JP2018510881A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510881A5 JP2018510881A5 JP2017550603A JP2017550603A JP2018510881A5 JP 2018510881 A5 JP2018510881 A5 JP 2018510881A5 JP 2017550603 A JP2017550603 A JP 2017550603A JP 2017550603 A JP2017550603 A JP 2017550603A JP 2018510881 A5 JP2018510881 A5 JP 2018510881A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- cells
- monoclonal antibody
- combined therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 17
- 108010087819 Fc receptors Proteins 0.000 claims description 12
- 102000009109 Fc receptors Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 2
- 206010063916 Metastatic gastric cancer Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 229950002916 avelumab Drugs 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 229960000455 brentuximab vedotin Drugs 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 229960004137 elotuzumab Drugs 0.000 claims description 2
- 229960000578 gemtuzumab Drugs 0.000 claims description 2
- 102000055277 human IL2 Human genes 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 14
- 229940124597 therapeutic agent Drugs 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 1
- 229940126590 dalatumumab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139258P | 2015-03-27 | 2015-03-27 | |
| US62/139,258 | 2015-03-27 | ||
| PCT/US2016/024318 WO2016160602A2 (en) | 2015-03-27 | 2016-03-25 | Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020133495A Division JP7000512B2 (ja) | 2015-03-27 | 2020-08-06 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510881A JP2018510881A (ja) | 2018-04-19 |
| JP2018510881A5 true JP2018510881A5 (enExample) | 2019-05-09 |
| JP6748105B2 JP6748105B2 (ja) | 2020-08-26 |
Family
ID=57006343
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550603A Active JP6748105B2 (ja) | 2015-03-27 | 2016-03-25 | がん治療のための遺伝子改変ｎｋ−９２細胞およびモノクローナル抗体 |
| JP2020133495A Active JP7000512B2 (ja) | 2015-03-27 | 2020-08-06 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2021208864A Active JP7328314B2 (ja) | 2015-03-27 | 2021-12-23 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2023126658A Active JP7557704B2 (ja) | 2015-03-27 | 2023-08-03 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2024146060A Active JP7766151B2 (ja) | 2015-03-27 | 2024-08-28 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020133495A Active JP7000512B2 (ja) | 2015-03-27 | 2020-08-06 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2021208864A Active JP7328314B2 (ja) | 2015-03-27 | 2021-12-23 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2023126658A Active JP7557704B2 (ja) | 2015-03-27 | 2023-08-03 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2024146060A Active JP7766151B2 (ja) | 2015-03-27 | 2024-08-28 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10456420B2 (enExample) |
| EP (1) | EP3273993A4 (enExample) |
| JP (5) | JP6748105B2 (enExample) |
| KR (3) | KR20250009013A (enExample) |
| CN (4) | CN117379460A (enExample) |
| AU (3) | AU2016243120B2 (enExample) |
| CA (1) | CA2977423A1 (enExample) |
| HK (2) | HK1249854A1 (enExample) |
| IL (4) | IL287051B (enExample) |
| WO (1) | WO2016160602A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3273993A4 (en) * | 2015-03-27 | 2018-11-07 | Nantkwest, Inc. | Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer |
| EP3458485B1 (en) | 2016-05-19 | 2021-12-29 | The General Hospital Corporation | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
| EP3532077A4 (en) * | 2016-10-28 | 2020-06-10 | Nant Holdings IP, LLC | Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death |
| US20180221463A1 (en) * | 2017-01-13 | 2018-08-09 | The Chinese University Of Hong Kong | Modified NK Cells and Uses Thereof |
| EP3592845A4 (en) | 2017-03-08 | 2020-12-30 | Nantkwest, Inc. | NK-92 HANK003 MODIFIED CELLS FOR THE CLINIC |
| CA3128202A1 (en) * | 2017-05-11 | 2018-11-15 | Nantkwest, Inc. | Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment |
| US20190321402A1 (en) * | 2018-04-19 | 2019-10-24 | Onkimmune Limited | Nk cells for use with anitbodies in cancer therapy |
| CN108531458A (zh) * | 2018-04-27 | 2018-09-14 | 赛诺（深圳）生物医药研究有限公司 | 治疗肿瘤的基因工程自然杀伤细胞产品 |
| US20210267190A1 (en) | 2018-07-10 | 2021-09-02 | Nantkwest, Inc. | Cryopreservation |
| CN119752801A (zh) * | 2018-08-01 | 2025-04-04 | 南克维斯特公司 | 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统 |
| WO2020051363A1 (en) * | 2018-09-07 | 2020-03-12 | Nantbio, Inc. | Targeted il-12 treatments and methods to stimulate hank and nk92mi cells |
| KR102533540B1 (ko) * | 2018-10-31 | 2023-05-17 | 난트퀘스트, 인크. | Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거(elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells) |
| KR102665280B1 (ko) * | 2018-10-31 | 2024-05-10 | 난트퀘스트, 인크. | Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거 |
| CA3117936A1 (en) * | 2018-11-26 | 2020-06-04 | Immunitybio, Inc. | Il-2 dependent nk-92 cells with stable fc receptor expression |
| CN119040363A (zh) * | 2019-03-15 | 2024-11-29 | 河谷细胞有限公司 | 重组erIL-15 NK细胞 |
| US12085571B2 (en) | 2019-06-13 | 2024-09-10 | Immunitybio, Inc. | Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags |
| CA3148608A1 (en) * | 2019-07-26 | 2021-02-04 | Immunitybio, Inc. | Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis |
| CN115190910A (zh) * | 2019-11-20 | 2022-10-14 | 免疫生物公司 | 细胞介导的免疫增强分子到肿瘤微环境中的瞬时递送 |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| CA3201621A1 (en) | 2020-12-03 | 2022-06-09 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
| EP4297769A2 (en) * | 2021-02-19 | 2024-01-03 | Preet M. Chaudhary | Single-chain and multi-chain synthetic antigen receptors for diverse immune cells |
| CN116948012B (zh) * | 2022-04-13 | 2024-07-26 | 星奕昂(上海)生物科技有限公司 | 增强细胞功能的cd16抗剪切突变体 |
| WO2024064824A2 (en) | 2022-09-21 | 2024-03-28 | Yale University | Compositions and methods for identification of membrane targets for enhancement of nk cell therapy |
| WO2025158400A1 (en) | 2024-01-24 | 2025-07-31 | Yale University | Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy |
| US20250298030A1 (en) * | 2024-03-20 | 2025-09-25 | Immunitybio, Inc. | Compositions and Methods for NK-92 Cells Expressing Native CD16 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7583797B2 (en) * | 2000-07-10 | 2009-09-01 | Broadcom Corporation | Single ended analog front end |
| WO2003101485A1 (en) * | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| JP2008505071A (ja) * | 2004-07-02 | 2008-02-21 | アヴァリス・アクチエボラーグ | 細胞を遺伝学的に活性化する方法、および、該細胞の使用 |
| DE602005016683D1 (de) | 2004-07-10 | 2009-10-29 | Fox Chase Cancer Ct | Genetisch modifizierte, menschliche, natürliche killerzellenlinien: |
| EP2161339A1 (en) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC with modified NK92 cells |
| RU2715038C2 (ru) * | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
| US9078488B1 (en) * | 2014-09-30 | 2015-07-14 | Nike, Inc. | Article of footwear incorporating a lenticular knit structure |
| EP3273993A4 (en) * | 2015-03-27 | 2018-11-07 | Nantkwest, Inc. | Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer |
-
2016
- 2016-03-25 EP EP16773863.2A patent/EP3273993A4/en active Pending
- 2016-03-25 HK HK18109327.5A patent/HK1249854A1/zh unknown
- 2016-03-25 KR KR1020257000202A patent/KR20250009013A/ko active Pending
- 2016-03-25 KR KR1020227036402A patent/KR102751730B1/ko active Active
- 2016-03-25 IL IL287051A patent/IL287051B/en unknown
- 2016-03-25 AU AU2016243120A patent/AU2016243120B2/en active Active
- 2016-03-25 IL IL301331A patent/IL301331A/en unknown
- 2016-03-25 IL IL294982A patent/IL294982B2/en unknown
- 2016-03-25 IL IL254214A patent/IL254214B2/en unknown
- 2016-03-25 US US15/529,848 patent/US10456420B2/en active Active
- 2016-03-25 CA CA2977423A patent/CA2977423A1/en active Pending
- 2016-03-25 CN CN202311097228.2A patent/CN117379460A/zh active Pending
- 2016-03-25 KR KR1020177030593A patent/KR102460387B1/ko active Active
- 2016-03-25 WO PCT/US2016/024318 patent/WO2016160602A2/en not_active Ceased
- 2016-03-25 CN CN201680019087.4A patent/CN107427578A/zh active Pending
- 2016-03-25 HK HK18106805.2A patent/HK1247117A1/zh unknown
- 2016-03-25 CN CN202110908609.9A patent/CN113604435A/zh active Pending
- 2016-03-25 JP JP2017550603A patent/JP6748105B2/ja active Active
- 2016-03-25 CN CN202210150391.XA patent/CN114533867A/zh active Pending
-
2019
- 2019-08-15 US US16/541,847 patent/US10736921B2/en active Active
-
2020
- 2020-06-17 US US16/903,882 patent/US11000550B2/en active Active
- 2020-08-06 JP JP2020133495A patent/JP7000512B2/ja active Active
-
2021
- 2021-03-30 US US17/217,839 patent/US11207350B2/en active Active
- 2021-11-09 AU AU2021266225A patent/AU2021266225B2/en active Active
- 2021-11-18 US US17/530,211 patent/US12384852B2/en active Active
- 2021-12-23 JP JP2021208864A patent/JP7328314B2/ja active Active
-
2023
- 2023-08-03 JP JP2023126658A patent/JP7557704B2/ja active Active
-
2024
- 2024-08-28 JP JP2024146060A patent/JP7766151B2/ja active Active
-
2025
- 2025-04-11 AU AU2025202587A patent/AU2025202587A1/en active Pending
- 2025-07-17 US US19/272,876 patent/US20250340664A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510881A5 (enExample) | ||
| Hou et al. | Navigating CAR-T cells through the solid-tumour microenvironment | |
| Raghani et al. | Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies | |
| Ochoa et al. | Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells | |
| EP2513146B1 (en) | Antibodies against ror1 capable of inducing cell death of cll | |
| CN108473572B (zh) | 用于治疗血源性癌症的免疫检查点抑制剂 | |
| JP2018500006A5 (enExample) | ||
| JP2018517415A5 (enExample) | ||
| JP2019511222A5 (enExample) | ||
| RS63574B1 (sr) | Metode za povećanje efikasnosti imuno ćelija | |
| JP2017506217A5 (enExample) | ||
| JP2016520074A5 (enExample) | ||
| JP2009541492A5 (enExample) | ||
| JP2019507582A5 (enExample) | ||
| JP2014528696A (ja) | 前立腺特異幹細胞抗原に対する抗体およびその使用 | |
| IL303269A (en) | Genetically engineered cells and uses thereof | |
| TW201110981A (en) | Combination therapy of an afucosylated CD20 antibody with fludarabine and/or mitoxantrone | |
| WO2022150732A3 (en) | Chimeric receptor therapy | |
| EP3291833A1 (en) | Nk cells and antibodies for cancer treatment | |
| CA3189137A1 (en) | Methods and compositions for stimulating gamma delta t cells | |
| JP2018506287A5 (enExample) | ||
| Danhof et al. | CARs and other T cell therapies for MM: the clinical experience | |
| Fan et al. | AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells | |
| Schultz et al. | New developments in immunotherapy for pediatric solid tumors | |
| JP2021505190A5 (enExample) |